[1]
|
李辉章, 毛伟敏, 汪祥辉, 余传定, 杜灵彬. 2009年浙江省恶性肿瘤发病与死亡情况分析[J]. 中国预防医学杂志, 2013, 47(7): 592-596.
|
[2]
|
李毅, 张临友, 张永强, 等. 手术治疗对早期小细胞肺癌的疗效观察[J]. 哈尔滨医科大学学报, 2013, 47(2): 181-183.
|
[3]
|
Dai, C., Shen, J., Ren, Y., et al. (2016) Choice of Surgical Procedure for Patients with Non-Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study. Journal of Clinical Oncology, 34, 3175-3182. https://doi.org/10.1200/jco.2015.64.6729
|
[4]
|
Yang, H.X., Woo, K.M., Sima, C.S., et al. (2017) Long-Term Survival Based on the Surgical Approach to Lobectomy for Clinical Stage I Nonsmall Cell Lung Cancer: Comparison of Robotic, Video-Assisted Thoracic Surgery, and Thoracotomy Lobectomy. Annals of Surgery, 265, 431-437. https://doi.org/10.1097/sla.0000000000001708
|
[5]
|
Lara Jr., P.N., Natale, R., Crowley, J., et al. (2009) Phase III Trial of Irinotecan/Cisplatin Compared with Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results from SWOG S0124. Journal of Clinical Oncology, 27, 2530-2535. https://doi.org/10.1200/JCO.2008.20.1061
|
[6]
|
Jiang, J., Liang, X., Zhou, X., et al. (2013) Non-Platinum Doublets Were as Effective as Platinum-Based Doublets for Chemotherapy-Naïve Advanced Non-Small-Cell Lung Cancer in the Era of Third-Generation Agents. Journal of Cancer Research and Clinical Oncology, 139, 25-38. https://doi.org/10.1007/s00432-012-1294-z
|
[7]
|
Scagliotti, G.V., Parikh, P., von Pawel, J., et al. (2008) Phase III Study Comparing Cisplatin plus Gemcitabine with Cisplatin plus Pemetrexed in Chemotherapy-Naive Patients with Advanced-Stage Non-Small-Cell Lung Cancer. Journal of Clinical Oncology, 26, 3543-3551. https://doi.org/10.1200/JCO.2007.15.0375
|
[8]
|
Ardizzoni, A. (2004) Topotecan in the Treatment of Recurrent Small Cell Lung Cancer: An Update. Oncologist, 9, 4-13.
|
[9]
|
De Ruysscher, D., Pijls-Johannesma, M., Vansteenkiste, J., et al. (2006) Systematic Review and Meta-Analysis of Randomised, Controlled Trials of the Timing of Chest Radi-otherapy in Patients with Limited-Stage, Small-Cell Lung Cancer. Annals of Oncology, 17, 543-552.
|
[10]
|
Takahashi, T., Yamanaka, T., Seto, T., et al. (2017) Prophylactic Cranial Irradiation versus Observation in Patients with Exten-sive-Disease Small-Cell Lung Cancer: A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 18, 663-671. https://doi.org/10.1016/S1470-2045(17)30230-9
|
[11]
|
应申鹏, 刘艳梅, 娄鹏荣, 等. 局部晚期非小细胞肺癌根治性放疗患者感染病原菌分布与危险因素分析[J]. 中华医院感染学杂志, 2016, 26(1): 95-97.
|
[12]
|
林展, 严浩林, 朱海生, 等. 阿米福汀在局部晚期非小细胞肺癌放疗中的作用研究[J]. 中国全科医学, 2013, 16(11): 1247-1249.
|
[13]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
|
[14]
|
Lund, E.L., Thorsen, C., Pedersen, M.W., Junker, N. and Kristjansen, P.E. (2000) Relationship between Vessel Density and Expression of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Small Cell Lung Cancer in Vivo and Invitor. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 6, 4287-4291.
|
[15]
|
Rudin, C.M., Pietanza, M.C., Bauer, T.M., Ready, N., Morgensztern, D., Glisson, B.S. and Investigators, S. (2017) Rovalpituzumab Tesirine, a DLL3-Targeted Antibody-Drug Conjugate, in Recurrent Small Cell Lung Cancer: A First-in-Human, First-in-Class, Open-Label, Phase 1 Study. The Lancet Oncology, 18, 42-51.
https://doi.org/10.1016/S1470-2045(16)30565-4
|
[16]
|
Mollaoglu, G., Guthrie, M.R., Bohm, S., Bragelmann, J., Can, I., Ballieu, P.M. and Oliver, T.G. (2017) MYC Drives Progression of Small Cell Lung Cancer to a Variant Neu-roendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 31, 270-285. https://doi.org/10.1016/j.cell.2016.12.005
|
[17]
|
Melichar, B., Adenis, A., Lockhart, A.C., Bennouna, J., Dees, E.C., Kayaleh, O. and Schusterbauer, C. (2015) Safety and Activity of Alisertib, an Investigational Aurora Kinase A Inhibitor, in Patients with Breast Cancer, Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, and Gastro-Oesophageal Adenocarcinoma: A Five-Arm Phase 2 Study. The Lancet Oncology, 16, 395-405.
https://doi.org/10.1016/S1470-2045(15)70051-3
|
[18]
|
Janku, F., Garrido-Laguna, I., Petruzelka, L.B., et al. (2011) Noveltherapeutic Targets in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 6, 1601-1612. https://doi.org/10.1097/JTO.0b013e31822944b3
|
[19]
|
Rosell, R., Moran, T., Queralt, C., et al. (2009) Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. The New England Journal of Medicine, 361, 958-967. https://doi.org/10.1056/NEJMoa0904554
|
[20]
|
Juan, O. and Popat, S. (2017) Treatment Choice in Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Carcinoma: Latest Evidence and Clinical Implications. Therapeutic Advances in Medical Oncology, 9, 201-216. https://doi.org/10.1177/1758834016687262
|
[21]
|
Wirth, S.M. (2015) Afatinib in Non-Small Cell Lung Cancer. Journal of the Advanced Practitioner in Oncology, 6, 448-455.
|
[22]
|
Rosell, R., Carcereny, E., Gervais, R., et al. (2012) Erlotinib versus Standard Chemotherapy as First-Line Treatment for European Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer (EURTAC): A Multicentre, Open-Label, Randomised Phase 3 Trial. The Lancet Oncology, 13, 239-246.
https://doi.org/10.1016/S1470-2045(11)70393-X
|
[23]
|
Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2015) Im-mune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 27, 450-461. https://doi.org/10.1016/j.cell.2015.03.001
|
[24]
|
Morgensztern, D. and Herbst, R.S. (2016) Nivolumab and Pem-brolizumab for Non-Small Cell Lung Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22, 3713-3717.
|
[25]
|
Antonia, S.J., Lopez-Martin, J.A., Bendell, J., Ott, P.A., Taylor, M., Eder, J.P. and Calvo, E. (2016) Nivolumab Alone and Nivolumab plus Ipilimumab in Recurrent Small-Cell Lung Cancer (CheckMate032): A Multicentre, Open-Label, Phase 1/2 Trial. The Lancet Oncology, 17, 883-895. https://doi.org/10.1016/S1470-2045(16)30098-5
|
[26]
|
Reck, M., Rodriguez-Abreu, D., Robinson, A.G., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833.
https://doi.org/10.1056/NEJMoa1606774
|
[27]
|
刘琳, 莫庆国, 杨旭, 等. CT引导下碘125粒子植入对肺癌患者的疗效影响[J]. 齐齐哈尔医学院学报, 2017, 38(23): 2759-2761.
|
[28]
|
王俊杰, 修典荣, 冉维强. 放射性粒子组织间近距离治疗肿瘤[M]. 第2版, 北京: 北京医科大学出版社, 2004: 24-25, 66-97.
|
[29]
|
王俊杰, 庄永志. 放射性粒子近距离治疗肿瘤[J]. 中国微创外科杂志, 2001, 1(3): 187-191.
|
[30]
|
罗开元. 实用组织间植入内放射治疗恶性肿瘤学[M]. 北京: 人民卫生出版社, 2008: 9-16.
|
[31]
|
Herfarh, K.K., Debus, J., Lohr, F., et al. (2000) Extracranial Steteotcetic Radiation Therapy: Set-Up Accuracy of Patients Treated for Liver Metastases. International Journal of Radiation Oncology, Biology, Physics, 46, 329-335.
https://doi.org/10.1016/S0360-3016(99)00413-7
|
[32]
|
Nakamura, H., Yasui, Y., Saito, N., et al. (2006) DNA Re-pair Defect in AT Cells and Their Hypersensitivity to Low-Dose-Rate Radiation. Radial Resolution, 165, 277-282. https://doi.org/10.1667/RR3519.1
|
[33]
|
Helton, W.S. (2004) Minmizing Comlications with Radiofrequency Abla-tion for Liver Cancer: The Importance of Properly Controlled Clinical Trials and Standardized Reporting. Annals of Surgery, 239, 459-463.
https://doi.org/10.1097/01.sla.0000120150.95389.ba
|
[34]
|
Sugawara, A., Nakashima, J., Shigematusu, N., et al. (2009) Prediction of Seed Migration after Transperineal Interstitial Prostate Brachytherapy with I-125 Free Seeds. Brachytherapy, 8, 52-56.
https://doi.org/10.1016/j.brachy.2008.10.003
|
[35]
|
孙保军, 邵静, 邵梦扬. COEP方案联合益气清肺胶囊治疗小细胞肺癌84例[J]. 河南中医, 2008, 202(10): 42-43.
|
[36]
|
李华, 马箐, 艾萍, 等. 中药预防肿瘤化疗后白细胞减少症随机对照试验的系统评价及Meta分析[J]. 中国中西医结合杂志, 2015, 35(2): 157-166.
|
[37]
|
石星, 丁乾, 杨勤. 香菇多糖联合化疗在治疗晚期非小细胞肺癌的作用[J]. 中国肿瘤, 2007, 16(11): 946.
|